Chemistry:Minzasolmin
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
N-[(2R)-1-(1H-indol-3-yl)hexan-2-yl]-2-(4-methylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C23H31N5OS | |
| Molar mass | 425.60 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Minzasolmin (development names DLX313 and UCB0599) is an experimental small-molecule drug developed for Parkinson's disease that is designed to prevent misfolding of α-synuclein.[1][2]
References
- ↑ Schwarz, Thomas C.; Beier, Andreas; Ledolter, Karin; Gossenreiter, Thomas; Höfurthner, Theresa; Hartl, Markus; Baker, Terry S.; Taylor, Richard J. et al. (11 April 2023). "High-resolution structural information of membrane-bound α-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599". Proceedings of the National Academy of Sciences 120 (15): e2201910120. doi:10.1073/pnas.2201910120. PMID 37027427. Bibcode: 2023PNAS..12001910S.
- ↑ Price, Diana L.; Khan, Asma; Angers, Rachel; Cardenas, Alvaro; Prato, Maria Key; Bani, Massimo; Bonhaus, Douglas W.; Citron, Martin et al. (17 July 2023). "In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease" (in en). npj Parkinson's Disease 9 (1): 114. doi:10.1038/s41531-023-00552-7. ISSN 2373-8057. PMID 37460603.
 |  |
